Results 141 to 150 of about 54,667 (268)

A 58‐year‐old woman experiencing occasional dizziness, impaired awareness, and deep feeling of fear

open access: yes
Brain Pathology, EarlyView.
Alessandro Selvaggini   +5 more
wiley   +1 more source

Developmental stuttering with common and complex phenotypes

open access: yesDevelopmental Medicine &Child Neurology, EarlyView.
Aim To describe the phenotypic spectrum associated with stuttering. Method Individuals with current or resolved developmental stuttering self‐referred. Surveys assessed stuttering characteristics (onset, negative impact, family history) and health (early development, other conditions). Speech and non‐verbal intelligence were assessed using conversation
Sarah E. Horton   +6 more
wiley   +1 more source

Cognitive and emotional mechanisms underlying migraine quality of life

open access: yesHeadache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective This study was conducted to examine how migraine‐related illness perceptions, shame, and psychological distress are associated with migraine‐specific quality of life, and to test a serial mediation model in which illness perceptions relate to quality of life via shame and psychological distress.
Shiri Shinan‐Altman   +1 more
wiley   +1 more source

Migraine with comorbid fibromyalgia: psychological burden and impact on frequency and severity of migraine attacks. [PDF]

open access: yesFront Neurol
Hassan A   +11 more
europepmc   +1 more source

Online interest in calcitonin gene‐related peptide‐therapies: An infodemiology study using Google trends

open access: yesHeadache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective To evaluate changes in public interest in calcitonin gene‐related peptide therapies associated with major product lifecycle milestones using online search data from the United States and Europe. Background Calcitonin gene‐related peptide therapies have transformed migraine treatment, but the impact of key product lifecycle milestones
Bradley Ong   +5 more
wiley   +1 more source

Weight loss with atogepant in the long‐term treatment of migraine: An interim analysis of a safety endpoint from a phase 3, multicenter, open‐label, 156‐week extension study

open access: yesHeadache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective To assess weight loss with atogepant 60 mg once daily during long‐term treatment of chronic migraine (CM) and episodic migraine (EM) among participants previously failed by two to four classes of conventional oral preventive medications.
Dale S. Bond   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy